Canada’s pot stocks may be overvalued but all that hype and hoopla around the nascent cannabis space shouldn’t be overlooked, says equity manager John Zechner, who argues that, for the time being, at least, the pot sector has a lot of momentum going for it. It’s been an historic week for Canada and cannabis, as […]
The Cantech Letter Cannabis section is brought to you by ABCann Medicinals. Organically grown standardized marijuana. Click on the logo above for more info.
Canopy Growth Corp CEO Linton says big pharma should be very afraid of WEED
The legislation has been approved and a timeframe has been established. Now all that’s left is for a whole country’s distribution and retail network to go from zero to 60 in a few months. However it all plays out, Canopy Growth Corp’s (TSX:WEED. NYSE:CGC) Bruce Linton says he won’t be taking any vacation days this […]
The street is running out of excuses to not own Hydropothecary, Echelon says
The graduation of The Hydropothecary Corp (TSXV:THCX) from the TSX Venture Exchange to the TSX could be a catalyst to unlock value, Echelon Wealth Partners analyst Russell Stanley says. On Friday, THCX will graduate to the TSX and ring the opening bell at the exchange. Management also announced it will seek shareholder approval to change […]
Expect a flurry of cannabis supply agreements over next few weeks, PI Financial says
With the federal government having now decided on an opening day for Canada’s legal rec marijuana business, we should expect the provincial supply agreements to come fast and furious, says Jason Zandberg, analyst with PI Financial, who estimates that a fully up-and-running market will produce $10.2 billion in annual sales. Yesterday, Prime Minister Justin Trudeau […]
MedReleaf shareholders should take the Aurora Cannabis deal, PI Financial says
Cannabis producer MedReleaf Corp (TSX:LEAF) reported quarterly earnings that show significant revenue growth from its cannabis oil sales, says Jason Zandberg of PI Financial, who has changed his recommendation from “Buy” to “Tender,” regarding the terms of the Aurora Cannabis (TSX:ACB) takeover. Yesterday, Markham, Ontario-based MedReleaf announced its Q4FY18 financials, with CEO Neil Closner highlighting […]
Canopy Growth Corp has earned its high share price, this advisor says
Legal weed is almost here, which means that Canada’s pot companies can get ready to harvest those crops and start stocking shelves. And none are expected to make a bigger splash than Canopy Growth Corp (TSX:WEED, NYSE:CGC), whose leadership in the space is indisputable, says Nicole Marchand of investor relations firm Grit Capital, who points […]
Invictus MD has a 125 per cent upside, Echelon Wealth says
A new export deal for licensed cannabis producer Invictus MD Strategies Corp (TSXV:GENE) gets the approval of Echelon Wealth Partners analyst Russell Stanley, who says that at a 61 per cent discount to its closest peers, Invictus is a “Speculative Buy.” On Tuesday, Invictus announced that it had signed a non-binding letter of intent (LOI) […]
Canopy Growth Corp’s huge cash position could produce a surprise: GMP
His price target is roughly the same as the current price of the stock, but GMP Securities analyst Martin Landry thinks Canopy Growth Corp’s (TSX:WEED) huge treasure chest could lead to an upside surprise. On June 15, WEED announced that it had upsized its previously announced offering of convertible senior notes due 2023 to $500-million, […]
Aurora Cannabis is acting like a drunken sailor, Frank Mersch says
Aurora Cannabis (TSX:ACB) may be making waves these days with its high profile acquisitions, but can the company pull it all together come rec legalization? The jury is still out, but there’s a lot to worry about, says Frank Mersch, chief strategist with Jamekk Capital Management, whose company is shorting ACB. Earlier this week, licensed […]
GW Pharmaceuticals is still undervalued, Beacon Securities says
He regards the company as the “undisputed global leader cannabinoid-derived pharmaceuticals”. Today, Beacon Securities analyst David Kideckel initiated coverage of GW Pharmaceuticals (OTCBB:GWPH) with a “Buy” rating and a one-year price target of (U.S.) $200.00, implying a return of 32 per cent at the time of publication. The analyst thinks there is a strong likelihood […]
- 1
- 2
- 3
- …
- 34
- Next Page »